Overview

A Study of AL102 in Patients With Progressing Desmoid Tumors

Status:
Recruiting
Trial end date:
2025-02-21
Target enrollment:
Participant gender:
Summary
The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ayala Pharmaceuticals, Inc,